Feature | March 27, 2012

New Medicare Rule for ICDs Adds Cost Without Improving Outcomes

March 27, 2012 — The cost to place an implantable cardioverter-defibrillator (ICD) increased by $844 per case after a new requirement from the Centers for Medicare and Medicaid Services (CMS) went into effect in February 2010, which has added little additional benefit for patients. This was according to research presented during the American College of Cardiology's (ACC) 61st Annual Scientific Session this week in Chicago.

That cost, if applied to the approximately 150,000 ICDs implanted in the United States each year, translates to $126 million in additional medical costs. The cost increase results from a new CMS requirement mandating that practitioners providing deep sedation be independent from the practitioner performing an invasive procedure. Previously, nurses administered limited deep sedation under the careful scrutiny of the implanting physician during ICD procedures; now, the implants require an additional physician such as an anesthesiologist.

“There was little evidence to support the policy change with regard to patient safety or outcomes,” said Osama Abdel-Hafez, M.D., an internal medicine resident at the Indiana University School of Medicine and the study’s lead author. “A policy that increases costs significantly without improvement in patient outcomes should be further reviewed.”

ICDs are small, battery-powered devices implanted in the chests of those at risk for sudden cardiac arrest. If the device detects a dangerous change in heart rhythm, it issues an electrical shock or other therapy to restore a normal heartbeat.

Patients remain conscious throughout most of an ICD implantation procedure, except for a brief period when doctors test the device by shocking the patient, which can be painful and requires deeper sedation.

“Deep sedation is not without complications,” Abdel-Hafez said. “However, there should be better selection of cases that need an anesthesiologist’s services. The CMS requirement was a blanket policy that covered all patients.”

A study from the same research team showed ICD implantation procedures that last longer in duration or that involve specific types of devices, such as biventricular ICDs, have a higher rate of sedation-related complications. Abdel-Hafez said having an anesthesiologist perform the sedation in such cases would make sense. Differentiating between higher- and lower-risk procedures could help improve patient outcomes without imposing unnecessary cost burdens, he added.

The researchers reviewed 431 ICD implants performed at Indiana University Health - Methodist Hospital. Just more than half (243) were performed before the February 2010 policy change; 188 were performed after. After the policy change, patients spent an extra day in the hospital (on average, four days instead of three) and incurred an additional $844 in medical charges per case for a total of $158,000 in additional costs overall.

The study was self-funded by the Indiana University School of Medicine.

For more information: www.acc.org
 

Related Content

AtriCure, AtriClip PRO2 LAA Exclusion System, left atrial appendage, FDA clearance
Technology | Left Atrial Appendage (LAA) Occluders| April 29, 2016
April 29, 2016 — AtriCure Inc. announced U.S.
microtubules, heartbeat mechanics, Perelman School of Medicine study

Microtubules in a cardiomyocyte at rest (top) and when compressed. Image courtesy of the lab of Ben Prosser, Ph.D., Perelman School of Medicine, University of Pennsylvania

News | EP Lab| April 29, 2016
Using new high-resolution microscopy, researchers have found that molecular struts called microtubules (MT) interact...
Boston Scientific, FDA, ImageReady MR-Conditional Pacing System
Technology | EP Lab| April 28, 2016
Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for a suite of products deemed safe for...
Feature | Business| April 28, 2016 | Dave Fornell
 
Auris Surgical Robotics, acquisition, Hansen Medical
News | Robotic Systems| April 26, 2016
Auris Surgical Robotics Inc. and Hansen Medical Inc. announced that they have signed a definitive merger agreement...
post-operative atrial fibrillation, AFib, heart rate, rhythm control, ACC.16
News | Atrial Fibrillation| April 20, 2016
In the first large randomized trial to directly compare two approaches to preventing atrial fibrillation following...
St. Jude Medical, EnSite Precision cardiac mapping system, European release
Technology | EP Mapping and Imaging Systems| April 19, 2016
St. Jude Medical Inc. announced expansion of its EnSite Precision cardiac mapping system limited market release in...
cardiac arrest, out-of-hospital, antiarrhythmic drugs, New England Journal of Medicine Study, ACC.16
News | Sudden Cardiac Arrest| April 19, 2016
April 19, 2016 — Researchers have confirmed that certain heart rhythm medications, when given by paramedics to patien
St. Jude Medical, SJM, MultiPoint Pacing, CRT, cardiac resynchronization therapy, U.S. launch
Technology | Cardiac Resynchronization Therapy Devices (CRT)| April 18, 2016
St. Jude Medical Inc. announced the U.S. launch and first U.S. implants of the Quadra Assura MP cardiac...
cardiofit, vagus nerve stimulation for heart failure, bio control medical

An illustration showing the implant of the Cardiofit device.

Feature | Heart Failure| April 15, 2016
April 15, 2016 — A new implantable medical device intended to help patients with heart failure by stimulating the vag
Overlay Init